CEA protein antigen not checked
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “* By the percutaneous route with the multiple puncture device * CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix”In the company’s words, NCT02403505 on ClinicalTrials.gov
- Tested for
- Rectal Cancer
- Main trialPhase 1
- “Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.”In the company’s words, NCT02403505 on ClinicalTrials.gov
Other drugs for Rectal Cancer
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- DostarlimabGSK · Phase 3
- CalderasibMerck & Co. · Phase 3
- IP-001Immunophotonics, Inc. · Phase 2/3
- AdagrasibMirati Therapeutics Inc. · Phase 3
- EncorafenibPfizer · Phase 3
Coming up1
- 28 NovPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 28 Nov 2026 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026